
Salzburg’s SALK and Paracelsus Medical University treats 33 cancer patients on first day with new high-resolution Agility multileaf collimator (MLC)
Requiring only a quick upgrade to their existing Elekta Synergy® linear accelerator, physicians at SALK and Paracelsus Medical University began using the new Agility™* 160-leaf multileaf collimator (MLC), treating 33 patients on its first day. In its first month of Agility use, the center now treats 50 patients per day, comprising about 700 inpidual treatment sessions that have benefited from this breakthrough in cancer care.
Based on their experience, clinicians at the Salzburg clinic report that the Agility MLC’s new design provides them with more precise dose sculpting capabilities and remarkably lower non-therapeutic radiation dose delivered to the patient.
“We were astonished at the amount of healthy tissue dose reduction we could achieve,” he adds. “This capacity theoretically enables us to improve outcomes and reduce the potential for complications.”
Harnessing Agility’s unique ability to deliver high-resolution beam-shaping over a large 40cm x 40cm field, the medical center has used this new technology to treat virtually all indications, including stereotactic (SBRT/SRT) cases and other advanced IMRT therapies.
*Agility is not licensed for sale in all markets. Approval of indications may vary between different countries. Additional regulatory clearances may be required in some markets.